Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors

Annals of Oncology

Volumn 27, Issue 2, 2016, Pages 300-305

  Cierna, Z ^a   Mego, Michal ^b,c   Miskovska, V ^d   Machalekova, K ^e   Chovanec, M ^b,c   Svetlovska, D ^b   Hainova, K ^b,f   Rejlekova, K ^b,c   Macak, D ^b   Spanik, S ^d   Ondrus, D ^d   Kajo, K ^e   Mardiak, J ^b,c   Babal, P ^a,g  

^a Faculty of Medicine and Faculty Hospital   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c Faculty of Natural Sciences   (Slovakia)

^d St Elisabeth Cancer Institute   (Slovakia)

^e SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^f INSTITUTE OF CHEMISTRY   (Slovakia)

^g Faculty Hospital with Policlinics Skalica   (Slovakia)

Author keywords

Immunotherapy; Prognosis; Programmed death receptor 1; Programmed death ligand 1; Testicular germ cell tumors

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; CISPLATIN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; EMBRYONAL CARCINOMA; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEMINOMA; TESTIS TERATOMA; VISCERAL METASTASIS; YOLK SAC TUMOR; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CHORIOCARCINOMA; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; PROCEDURES; TESTICULAR NEOPLASMS; TRANSLATIONAL RESEARCH; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CHORIOCARCINOMA; CISPLATIN; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGRAMMED CELL DEATH 1 RECEPTOR; TESTICULAR NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; YOUNG ADULT;

EID: 84961654788     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv574     Document Type: Article

References (25)

1. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8: 1777-1781.
2. Einhorn LH. General Motors Cancer Research Prizewinners Laureates Lectures. Charles F. Kettering Prize. Clinical trials in testicular cancer. Cancer 1993; 71: 3182-3184.
3. Motzer RJ, Geller NL, Tan CC et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 1991; 67: 1305-1310.
4. Motzer RJ, Sheinfeld J, Mazumdar M et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000; 18: 2413-2418.
5. Mardiak J, Salek T, Sycova-Mila Z et al. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. Neoplasma 2005; 52: 497-501.
6. Feldman DR, Patil S, Trinos MJ et al. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer 2012; 118: 981-986.
7. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-242.
8. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813-824.
9. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 2014; 588: 368-376.
10. Cheng X, Veverka V, Radhakrishnan A et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013; 288: 11771-11785.
11. Noh H, Hu J, Wang X et al. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 2015; 13: 14.
12. Azuma K, Ota K, Kawahara A et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small-cell lung cancer. Ann Oncol 2014; 25: 1935-1940.
13. Kim JW, Eder JP. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology (Williston Park) 2014; 28(Suppl 3): 15-28.
14. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116: 1757-1766.
15. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66: 3381-3385.
16. Shi SJ, Wang LJ, Wang GD et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One 2013; 8: e76012.
17. Muenst S, Schaerli AR, Gao F et al. Expression of programmed death ligand 1 (PDL1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014; 146: 15-24.
18. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade:combinations in the clinic. Front Oncol 2014; 4: 385.
19. Fankhauser CD, Curioni-Fontecedro A, Allmann V et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer 2015; 113: 411-413.
20. Mostofi FK, Sesterhenn IA. Tumours of the testis and paratesticular tissue. In Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds), World Health Organization Classification of Tumours. International Agency for Research on Cancer (IARC). Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press 2004; 216-278.
21. Barbagallo F, Paronetto MP, Franco R et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol 2009; 217: 431-441.
22. Mego M, Cierna Z, Svetlovska D et al. PARP expression in germ cell tumours. J Clin Pathol 2013; 66: 607-612.
23. Ulisse S, Baldini E, Mottolese M et al. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. BMC Cancer 2010; 10: 151.
24. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
25. Cheng X, Dai H, Wan N et al. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege. Transplantation 2009; 87: 1778-1786.